

13. Hildebrandt B, Wust P, Ahlers O, et al. The cellular and molecular basis of hyperthermia. *Crit Rev Oncol Hematol*. 2002; 43(1): 33–56.
14. Haveman J, Smals OA, Rodermond HM. Effects of hyperthermia on the rat bladder: a pre-clinical study on thermometry and functional damage after treatment. *Int J Hyperthermia*. 2003; 19: 45–57.
15. Oei AL, Kok HP, Oei SB, et al. Molecular and biological rationale of hyperthermia as radio- and chemosensitizer. *Adv Drug Deliv Rev*. 2020; 163–164: 84–97.
16. Issels RD. Hyperthermia adds to chemotherapy. *European journal of cancer (Oxford, England: 1990)*. 2008; 44(17): 2546–2554.
17. Maeda H, Tsukigawa K, Fang J. A Retrospective 30 Years After Discovery of the Enhanced Permeability and Retention Effect of Solid Tumors: Next-Generation Chemotherapeutics and Photodynamic Therapy-Problems, Solutions, and Prospects. *Microcirculation (New York, NY: 1994)*. 2016; 23(3): 173–182.
18. Au JL, Wientjes MG. Combination intravesical hyperthermia and chemotherapy for bladder cancer. *Oncology (Williston Park)*. 2010; 26: 1155–60.
19. Inman BA, Etienne W, Rubin R, et al. The impact of temperature and urinary constituents on urine viscosity and its relevance to bladder hyperthermia treatment. *Int J Hyperthermia*. 2013; 29: 206–10.
20. van der Heijden AG, Dewhirst MW. Effects of hyperthermia in neutralising mechanisms of drug resistance in non-muscle-invasive bladder cancer. *Int J Hyperthermia*. 2016; 32(4): 434–45.
21. Franke K, Kettering M, Lange K, Kaiser WA, Hilger I. The exposure of cancer cells to hyperthermia, iron oxide nanoparticles, and mitomycin C influences membrane multidrug resistance protein expression levels. *Int J Nanomed*. 2013; 8: 351–63.
22. Evans SS, Repasky EA, Fisher DT. Fever and the thermal regulation of immunity: the immune system feels the heat. *Nature reviews Immunology*. 2015; 15(6): 335–349.
23. Milani V, Noessner E, Ghose S, et al. Heat shock protein 70: role in antigen presentation and immune stimulation. *Int J Hyperthermia*. 2002; 18(6): 563–575.
24. Arends TJ, Falke J, Lammers RJ, et al. Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. *World J Urol*. 2015; 33: 1411–17.
25. Ware MJ, Tinger S, Colbert KL, et al. Radiofrequency treatment alters cancer cell phenotype. *Sci Rep*. 2015; 5: 12083.
26. van Valenberg FJP, van der Heijden AG, Lammers RJM, et al. Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue. *Int J Hyperthermia*. 2018; 34(7): 988–993.
27. Curley SA, Palalon F, Sanders KE, Koshkina NV. The effects of non-invasive radiofrequency treatment and hyperthermia on malignant and nonmalignant cells. *Int J Environ Res Public Health*. 2014; 3: 11(9): 9142–53.
28. Lammers RJ, Witjes JA, Inman BA, et al. The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non muscle invasive bladder cancer: A systematic review. *Eur Urol*. 2011; 60: 81–93.
29. Brummelhuis ISG, Wimper Y, Witjes-van Os HGJM, et al. Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer. *Cancers*. 2021; 13: 377.
30. Colombo R, Da Pozzo LF, Lev A, et al. Local microwave hyperthermia and intravesical chemotherapy as bladder sparing treatment for selected multifocal and unresectable superficial bladder tumors. *J Urol*. 1998; 159: 783–7.
31. Brisuda A, Babjuk M, Stolz J. Intravezikální chemoterapie s využitím tepelné energie u pacientů s uroteriálním karcinomem močového měchýře bez invaze svaloviny. *Ces Urol*. 2017; 21(2): 122–128.